🔎 Trials Near Me

Home › Cardiomyopathy › Texas › Dallas

Cardiomyopathy clinical trials in Dallas, TX

6 studies for Cardiomyopathy are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

RecruitingPhase 3
  • Clinical Trial Site, Dallas
Ages 18 to 85 · All sexes · Updated Sep 16, 2026 · NCT07052903

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

RecruitingObservational study
  • Clinical Trial Site, Dallas
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07358078

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

RecruitingPhase 2
  • Children's Health Dallas, Dallas
Ages 0 to 16 · All sexes · Updated Aug 10, 2026 · NCT06080074

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

RecruitingPhase 3
  • University of Texas Southwestern, Dallas
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895

Danon Disease Natural History Study

RecruitingObservational study
  • University of Texas, Southwestern, Dallas
Ages 8 and older · All sexes · Updated Jul 28, 2026 · NCT06214507

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

RecruitingPhase 3
  • Baylor Scott & White Research Institute, Dallas
  • University of Texas Southwestern Medical Center, Dallas
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629

About Cardiomyopathy

Cardiomyopathy is a disease that causes the heart to become enlarged, thick, or stiff. Read about the different types, their symptoms, and treatments.

More about Cardiomyopathy on MedlinePlus

Cardiomyopathy trials in other cities

Other studies in Dallas

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.